A decade ago, EY created a metric, the Firepower Index, to understand how life sciences companies were most likely to use M&A to drive portfolio growth. I am pleased to share with you that our 2022 edition is now available. The report was launched on 10 January, during our virtual EY Firepower panels in conjunction with the annual JP Morgan Healthcare Conference.
News
Nottingham based contract research organisation (CRO) Cellomatics Biosciences has expanded its team with the appointment of senior molecular biologist, Dr Lara De Tomasi, in response to recent growth and the continued increase in demand for its bespoke preclinical and early discovery phase expertise.
London, UK, 10 February 2022: PharmaVentures today announced it has moved its operational headquarters from Oxford to London as part of its continued strategic expansion. The company will retain its remaining operational and administrative functions at its new registered office in Oxford.
Cambridge, United Kingdom, 10th February 2022 / Sciad Newswire / Domainex Ltd., a leading integrated medicines research services partner, today announces it has opened a facility of over 7,000 sq ft at Unity Campus in Sawston – Cambridge’s newest science and technology park encompassing Iconix Park and The Works, and owned by leading regional property and investment firm Howard Group.
The UK Government’s recently released “Levelling up White Paper” makes for interesting reading in the context of the life sciences sector.
In advance of a more in-depth review, here are some of the key points and my thoughts, focusing on two of the main areas of relevance to the sector: small company finance and R&D expenditure.
Cambridge UK: 07 February 2022
Bidwells LLP, widely recognized as a pioneer and the leading science & technology property adviser in the UK has become the latest Partner to join One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
London & Cambridge, United Kingdom, 3rd February 2022 / Sciad Newswire / Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, and Domainex Ltd., today announce a collaboration focused on developing small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s. Domainex, a leading integrated medicines research services partner, will provide fully integrated drug discovery services including assay biology, medicinal and computational chemistry.
CAMBRIDGE, UK (02 Feb 2022) – Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, today announced that the first close of its Series B financing has raised $42.5 million. The funds raised will be used to accelerate the development and commercialization of its eProtein™ desktop bioprinter.
Cambridge, UK, February 1, 2022 — Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors. The investment will fund the upcoming launch of ASPYRE-Lung, the company’s first commercial diagnostic assay based on its breakthrough molecular technology.